Michael C Braun1, Stacy M Herring1, Nisha Gokul1, Monique Monita1, Rebecca Bell1, Yaming Zhu1, Manuel L Gonzalez-Garay1, Scott E Wenderfer1, Peter A Doris2. 1. From the Department of Pediatrics, Baylor College of Medicine (M.C.B., S.E.W.), and Institute of Molecular Medicine (S.M.H., N.G., M.M., R.B., Y.Z., M.L.G.-G., P.A.D.), University of Texas Health Science Center at Houston. 2. From the Department of Pediatrics, Baylor College of Medicine (M.C.B., S.E.W.), and Institute of Molecular Medicine (S.M.H., N.G., M.M., R.B., Y.Z., M.L.G.-G., P.A.D.), University of Texas Health Science Center at Houston. peter.a.doris@uth.tmc.edu.
Abstract
BACKGROUND: The spontaneously hypertensive rat (SHR) strain exists in lines that contrast strongly in susceptibility to renal injury in hypertension. These inbred lines share common ancestry, and only 13% of their genomes arise from different ancestors. METHODS AND RESULTS: We used next gen sequencing to detect natural allelic variation in 5 genes of the immunoreceptor signaling pathway (IgH, Dok3, Src, Syk, and JunD) that arise from different ancestors in the injury-prone SHR-A3 and the resistant SHR-B2 lines. We created an intercross between these lines, and in the F2 progeny, we observed that the inheritance of haplotype blocks containing the SHR-A3 alleles of these 5 genes correlated with increased albuminuria and histological measures of renal injury. To test whether accumulated genetic variation in this pathway may create a therapeutic target in hypertensive renal injury, rats of both lines were treated with the immunosuppressant mycophenolate mofetil (MMF). MMF reduced proteinuria (albumin to creatinine ratio) from 6.6 to 1.2 mg/mg (P<0.001) in SHR-A3. Glomerular injury scores were reduced in MMF-treated SHR-A3 from 1.6 to 1.4 (P<0.002). Tubulo-interstitial injury was reduced in MMF-treated SHR-A3 from 2.62 to 2.0 (P=0.001). MMF treatment also reduced renal fibrosis in SHR-A3 (3.9 versus 2.0; P<0.001). CONCLUSIONS: Polygenic susceptibility to renal injury in hypertension arises in association with genetic variation in genes that participate in immune responses and is dramatically improved by reduction of immune system activity.
BACKGROUND: The spontaneously hypertensiverat (SHR) strain exists in lines that contrast strongly in susceptibility to renal injury in hypertension. These inbred lines share common ancestry, and only 13% of their genomes arise from different ancestors. METHODS AND RESULTS: We used next gen sequencing to detect natural allelic variation in 5 genes of the immunoreceptor signaling pathway (IgH, Dok3, Src, Syk, and JunD) that arise from different ancestors in the injury-prone SHR-A3 and the resistant SHR-B2 lines. We created an intercross between these lines, and in the F2 progeny, we observed that the inheritance of haplotype blocks containing the SHR-A3 alleles of these 5 genes correlated with increased albuminuria and histological measures of renal injury. To test whether accumulated genetic variation in this pathway may create a therapeutic target in hypertensive renal injury, rats of both lines were treated with the immunosuppressant mycophenolate mofetil (MMF). MMF reduced proteinuria (albumin to creatinine ratio) from 6.6 to 1.2 mg/mg (P<0.001) in SHR-A3. Glomerular injury scores were reduced in MMF-treated SHR-A3 from 1.6 to 1.4 (P<0.002). Tubulo-interstitial injury was reduced in MMF-treated SHR-A3 from 2.62 to 2.0 (P=0.001). MMF treatment also reduced renal fibrosis in SHR-A3 (3.9 versus 2.0; P<0.001). CONCLUSIONS: Polygenic susceptibility to renal injury in hypertension arises in association with genetic variation in genes that participate in immune responses and is dramatically improved by reduction of immune system activity.
Authors: Dominik N Muller; Erdenechimeg Shagdarsuren; Joon-Keun Park; Ralf Dechend; Eero Mervaala; Franziska Hampich; Anette Fiebeler; Xinsheng Ju; Piet Finckenberg; Jürgen Theuer; Christiane Viedt; Joerg Kreuzer; Harald Heidecke; Hermann Haller; Martin Zenke; Friedrich C Luft Journal: Am J Pathol Date: 2002-11 Impact factor: 4.307
Authors: B Rodríguez-Iturbe; H Pons; Y Quiroz; K Gordon; J Rincón; M Chávez; G Parra; J Herrera-Acosta; D Gómez-Garre; R Largo; J Egido; R J Johnson Journal: Kidney Int Date: 2001-06 Impact factor: 10.612
Authors: Huiling Wu; Gang Chen; Kate R Wyburn; Jianlin Yin; Patrick Bertolino; Josette M Eris; Stephen I Alexander; Alexandra F Sharland; Steven J Chadban Journal: J Clin Invest Date: 2007-10 Impact factor: 14.808
Authors: Peter S T Yuen; Stephen R Dunn; Takehiko Miyaji; Hideo Yasuda; Kumar Sharma; Robert A Star Journal: Am J Physiol Renal Physiol Date: 2004-02-17
Authors: Santosh S Atanur; Ana Garcia Diaz; Klio Maratou; Allison Sarkis; Maxime Rotival; Laurence Game; Michael R Tschannen; Pamela J Kaisaki; Georg W Otto; Man Chun John Ma; Thomas M Keane; Oliver Hummel; Kathrin Saar; Wei Chen; Victor Guryev; Kathirvel Gopalakrishnan; Michael R Garrett; Bina Joe; Lorena Citterio; Giuseppe Bianchi; Martin McBride; Anna Dominiczak; David J Adams; Tadao Serikawa; Paul Flicek; Edwin Cuppen; Norbert Hubner; Enrico Petretto; Dominique Gauguier; Anne Kwitek; Howard Jacob; Timothy J Aitman Journal: Cell Date: 2013-07-25 Impact factor: 41.582
Authors: Sivarajan Kumarasamy; Harshal Waghulde; Xi Cheng; Steven T Haller; Blair Mell; Basrur Abhijith; Usman M Ashraf; Ealla Atari; Bina Joe Journal: Physiol Genomics Date: 2018-03-23 Impact factor: 3.107
Authors: Isha S Dhande; Stacy M Cranford; Yaming Zhu; Sterling C Kneedler; M John Hicks; Scott E Wenderfer; Michael C Braun; Peter A Doris Journal: Hypertension Date: 2018-02-05 Impact factor: 10.190
Authors: Isha S Dhande; Sterling C Kneedler; Aniket S Joshi; Yaming Zhu; M John Hicks; Scott E Wenderfer; Michael C Braun; Peter A Doris Journal: Physiol Genomics Date: 2019-10-14 Impact factor: 3.107
Authors: Isha S Dhande; Yaming Zhu; Michael C Braun; M John Hicks; Scott E Wenderfer; Peter A Doris Journal: Physiol Genomics Date: 2016-12-23 Impact factor: 3.107
Authors: Sterling C Kneedler; Lauren E Phillips; Kayla R Hudson; Katharine M Beckman; Catalina A Lopez Gelston; Joseph M Rutkowski; Alan R Parrish; Peter A Doris; Brett M Mitchell Journal: Am J Physiol Renal Physiol Date: 2017-02-22
Authors: Mykola Mamenko; Isha Dhande; Viktor Tomilin; Oleg Zaika; Nabila Boukelmoune; Yaming Zhu; Manuel L Gonzalez-Garay; Oleh Pochynyuk; Peter A Doris Journal: J Am Soc Nephrol Date: 2015-11-16 Impact factor: 10.121
Authors: Isha S Dhande; Yaming Zhu; Sterling C Kneedler; Aniket S Joshi; M John Hicks; Scott E Wenderfer; Michael C Braun; Peter A Doris Journal: J Am Heart Assoc Date: 2020-02-20 Impact factor: 5.501